← Leaderboards
Roberto Di Maio
University Of Pittsburgh At Pittsburgh
$1,619,004
Attributed
$1,834,191
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $483.6K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,834,191 · 2
By mechanism
R01$1,403,816 · 1
R21$430,375 · 1
Top collaborators
- Marco Fazzari1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Laurie H Sanders$3,931,599
- Eric Eugene Kelley$2,318,020
- Alicia R Mathers$4,373,803
- Hulya Bayir$16,376,338
- Sruti Shiva$9,895,872
Others in their field
Other Emerging Leaders on “Novel Drug Class”
- Jeffrey Reich · Sparian Biosciences, Inc.$20,952,263
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$11,832,144
- Thomas Dick · Rbhs-New Jersey Medical School$11,796,925
- Terry Roemer · Prokaryotics, Inc.$11,053,778
- Crystal Mackall · Children'S Hosp Of Philadelphia$10,785,733
- Mary E Hamby · Cognition Therapeutics, Inc.$9,832,688
Research focus
Novel Drug ClassPathogenesisNadph OxidaseNon-Motor SymptomOxidative StressParkinsonian DisordersInflammatory ResponseMovement DisordersAnimal Disease ModelsNeuroinflammationEventNovel Therapeutic InterventionBrainParkinson DiseaseAffectCellsMediatingMitochondrial DysfunctionComplexConsensusEffective TherapyNerve DegenerationAge RelatedPathogenicity
Grant awards (4)
NADPH Oxidase 2 in Parkinson's Disease Pathogenesis$466,915
R01 · FY2025 · NS · contact PI
NADPH Oxidase 2 in Parkinson's Disease Pathogenesis$453,328
R01 · FY2024 · NS · contact PI
NADPH Oxidase 2 in Parkinson's Disease Pathogenesis$483,573
R01 · FY2023 · NS · contact PI
Protective actions of the anti-inflammatory drug candidate 10-nitro-oleic acid in Parkinsonâs disease$430,375
R21 · FY2019 · NS